Is pyrazinamide really the third drug of choice in the treatment of tuberculosis?
Loading...
Date
Authors
Koumbaniou, C.
Nicopoulos, C.
Vassiliou, M.
Manda-Stachouli, C.
Sakellariou, K.
Demou, G. S.
Constantopoulos, S. H.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Int J Tuberc Lung Dis
Book name
Book series
Book edition
Alternative title / Subtitle
Description
SETTING: University Hospital in a rural area of Greece. OBJECTIVE: Pyrazinamide (PZA) is recommended as the third drug in the 6-month regimens for tuberculosis. This has replaced previously satisfactory 9-month regimens with ethambutol (EMB). Several cases of severe hyperuricemia and at least one episode of acute arthritis in patients receiving PZA prompted us to study PZA prospectively with regard to these side effects. DESIGN AND SUBJECTS: Prospective study of 20 patients receiving PZA for tuberculosis compared to control patients with tuberculosis not receiving PZA. RESULTS: The study was discontinued with the twentieth patient when it became obvious that uric acid was elevated in all patients while on PZA and the last patient developed acute arthritis. This occurred in none of the control patients. CONCLUSION: Hyperuricemia should either be considered a significant side effect and make us reconsider PZA as the third drug of choice in tuberculosis, or it should be officially declared trivial by a major health organization. If so, it should be suggested to all health providers involved that there is no need to monitor uric acid in tuberculosis patients receiving PZA.
Description
Keywords
Adult, Aged, Antitubercular Agents/*adverse effects, Arthritis/chemically induced, Female, Humans, Male, Middle Aged, Prospective Studies, Pyrazinamide/*adverse effects, Tuberculosis/*drug therapy, Uric Acid/*blood
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/9712283
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής